Advicenne S.A. (ENXTPA: ALDVI)
Health Care · Pharmaceuticals · FR
€1.73
-1.26% today · +44.6% 1Y
Advicenne S.A. (ENXTPA: ALDVI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $29.76M and employs 11 people.
Over the last twelve months the share price has gained 44.6%, trading between 0.80 and 2.35.
Tweenvest scores Advicenne S.A. across four factors: quality 9/100, value 75/100, growth 100/100. Its strongest factor is growth.
ALDVI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.76M
- Revenue (TTM)
- $7.52M
- P/E
- —
- EPS
- -0.65
- Dividend yield
- —
- Beta (5Y)
- 0.93
- 52-week high
- €2.35
- 52-week low
- €0.80
- Avg volume (3M)
- —
- Shares outstanding
- 14.55M
- Employees
- 11
- Next earnings
- —
About Advicenne S.A.
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.
- ISIN
- FR0013296746
- Founded
- 2007
- Listed since
- Dec 6, 2017
- Exchange
- Euronext Paris
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,247.37 | -0.64% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $273.00 | +1.02% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.91 | -1.08% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.